利妥昔单抗治疗儿童激素抵抗型肾病综合征的系统综述
该系统综述纳入7项病例系列和1项开放标签随机对照试验,共226例激素抵抗型肾病综合征患儿,评估利妥昔单抗的疗效与安全性。结果显示46.4%患儿获得缓解,初始激素抵抗型缓解率40.8%,迟发型52.8%,仅报告5例严重不良事件。作者认为利妥昔单抗是颇具前景的治疗选择,需进一步随机临床试验验证。
要点
- 利妥昔单抗在儿童激素抵抗型肾病综合征中总缓解率为46.4%。
- 迟发型激素抵抗型缓解率(52.8%)高于初始型(40.8%)。
- 仅报告5例严重不良事件,安全性总体可接受。
核心结论
- 利妥昔单抗在儿童激素抵抗型肾病综合征中显示出令人满意的疗效与安全性,是颇具前景的治疗选择,需进一步随机临床试验验证。
研究设计与样本
- 系统综述,检索MEDLINE、Cochrane Library、Scopus和Web of Science截至2017年4月的研究。
- 纳入标准为临床试验或观察性研究,样本量至少5例,对象为接受利妥昔单抗治疗的儿童激素抵抗型肾病综合征患者。
- 最终纳入7项病例系列和1项开放标签随机对照试验,其中3项为多中心研究,共226例患者。
- 由2名研究者独立使用预设数据字段提取文献。
主要发现
- 226例患儿起病平均年龄为5.6±1.1岁,人均利妥昔单抗输注次数为3.1±1.1次。
- 89例(46.4%)获得缓解,其中初始激素抵抗型缓解率40.8%,迟发型缓解率52.8%。
- 微小病变型肾病初始应答良好者占63.2%,局灶节段性肾小球硬化占39.2%,另有弥漫性系膜细胞增生和IgM肾病各1例。
- 持续缓解率为18%至93.7%,观察到5例严重不良事件。
关键数值与推荐
- 研究纳入标准:临床试验或观察性研究,最小样本量5例,对象为儿童激素抵抗型肾病综合征患者。
- 缓解定义为观察到缓解,共89例(46.4%)达到缓解。
- 持续缓解范围18%至93.7%。
- 严重不良事件共5例。
临床怎么用
- 利妥昔单抗可作为儿童激素抵抗型肾病综合征的备选治疗,尤其对迟发型激素抵抗和微小病变型患儿可能获益更明显。
- 治疗期间需监测严重不良事件,目前证据来自小样本观察性研究和1项开放标签随机对照试验,决策时应结合个体情况。
局限性
- 纳入研究以病例系列为主,仅1项开放标签随机对照试验,证据等级有限。
- 研究间持续缓解率差异大(18%至93.7%),异质性明显。
- 检索截止2017年4月,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of rituximab in children with steroid-resistant nephrotic syndrome. STUDY DESIGN: A systematic review evaluating the efficacy and safety of rituximab in children with steroid-resistant nephrotic syndrome was performed. Data from studies, performed before April 2017 were collected, from MEDLINE, Cochrane Library, Scopus, and Web of Science. Study eligibility criteria included clinical trials and observational studies with a minimal sample size of 5 patients, regarding treatment with rituximab in children with steroid-resistant nephrotic syndrome. Independent extraction of articles by 2 investigators using predefined data fields was performed. RESULTS: We included 7 case series and 1 open-label randomized controlled trial. Among them, 3 studies were multicenter. A total of 226 patients were included. Mean age at onset was 5.6 ± 1.1 years. Mean number of rituximab administrations was 3.1 ± 1.1 infusions per patient. Remission was observed in 89 patients (46.4%). Remission was seen in 40.8% patients with initial steroid-resistant nephrotic syndrome and 52.8% patients with late steroid-resistant nephrotic syndrome. Good initial response to rituximab therapy was observed in 63.2% patients with minimal change nephrotic syndrome, 39.2% patients with focal and segmental glomerulosclerosis, 1 patient had diffuse mesangial hypercellularity, and 1 patient had IgM nephropathy. Sustained remission ranged from 18% to 93.7%. Five serious adverse events were observed. CONCLUSIONS: Rituximab exhibited a satisfactory profile regarding efficacy and safety indicating that this agent is a promising therapy for steroid-resistant nephrotic syndrome and should be further investigated by randomized clinical trials.
引用
- Jellouli M, Charfi R, Maalej B, et al. Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review. J Pediatr. 2018. PMID: 29680473. doi:10.1016/j.jpeds.2018.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。